~~~~ Idiocracy predicted that as we got dumber, we would start dropping words like "molecules" as a marketing ploy.
Posted on 03/11/2025 8:04:07 AM PDT by Twotone
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of the drug’s side effects such as nausea, constipation and significant loss of muscle mass.
The newly discovered molecule, BRP, acts through a separate but similar metabolic pathway and activates different neurons in the brain — seemingly offering a more targeted approach to body weight reduction.
“The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues,” said assistant professor of pathology Katrin Svensson, PhD. “That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.”
Svensson has co-founded a company to launch clinical trials of the molecule in humans in the near future.
Svensson is the senior author of the research, which was published March 5 in Nature. Senior research scientist Laetitia Coassolo, PhD, is the lead author of the study.
The study would not have been possible without the use of artificial intelligence to weed through dozens of proteins in a class called prohormones. Prohormones are biologically inert molecules that become active when they are cleaved by other proteins into smaller pieces called peptides; some of these peptides then function as hormones to regulate complex biological outcomes, including energy metabolism, in the brain and other organs. Katrin Svensson Katrin Svensson
Each prohormone can be divided in a variety of ways to create a plethora of functional peptide progeny. But with traditional methods of protein isolation, it’s difficult to pick peptide hormones (which are relatively rare) out of the biological soup of the much more numerous natural byproducts of protein degradation and processing.
The researchers focused on the prohormone convertase 1/3, which separates prohormones at specific amino acid sequences and is known to be involved in human obesity. One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite and blood sugar levels; semaglutide works by mimicking the effect of GLP-1 in the body. The team turned to artificial intelligence to help them identify other peptides involved in energy metabolism. Peptide Predictor
Instead of manually isolating proteins and peptides from tissues and using techniques like mass spectrometry to identify hundreds of thousands of peptides, the researchers designed a computer algorithm they named Peptide Predictor to identify typical prohormone convertase cleavage sites in all 20,000 human protein-coding genes. They then focused on genes that encode proteins that are secreted outside the cell — a key characteristic of hormones — and that have four or more possible cleavage sites. Doing so narrowed down the search to 373 prohormones, a manageable number to screen for their biological effects.
“The algorithm was absolutely key to our findings,” Svensson said.
Peptide Predictor predicted that prohormone convertase 1/3 would generate 2,683 unique peptides from the 373 proteins. Coassolo and Svensson focused on sequences likely to be biologically active in the brain. They screened 100 peptides, including GLP-1, for their ability to activate lab-grown neuronal cells.
As expected, the GLP-1 peptide had a robust effect on the neuronal cells, increasing their activity threefold over control cells. But a small peptide made up of just 12 amino acids bumped up the cells’ activity tenfold over controls. The researchers named this peptide BRP based on its parent prohormone, BPM/retinoic acid inducible neural specific 2, or BRINP2 (BRINP2-related-peptide).
When the researchers tested the effect of BRP on lean mice and minipigs (which more closely mirror human metabolism and eating patterns than mice do) they found that an intramuscular injection of BRP prior to feeding reduced food intake over the next hour by up to 50% in both animal models. Obese mice treated with daily injections of BRP for 14 days lost an average of 3 grams — due almost entirely to fat loss — while control animals gained about 3 grams over the same period. The mice also demonstrated improved glucose and insulin tolerance.
Behavioral studies of the mice and pigs found no differences in the treated animals’ movements, water intake, anxiety-like behavior or fecal production. And further studies of physiological and brain activity showed that BRP activates metabolic and neuronal pathways separate from those activated by GLP-1 or semaglutide.
The researchers hope to identify the cell-surface receptors that bind BRP and to further dissect the pathways of its action. They are also investigating how to help the peptide’s effects last longer in the body to allow a more convenient dosing schedule if the peptide proves to be effective in regulating human body weight.
“The lack of effective drugs to treat obesity in humans has been a problem for decades,” Svensson said. “Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans.”
Researchers from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia contributed to the work.
The study was funded by the National Institutes of Health (grants R01DK125260, P30DK116074, K99AR081618 and GM113854), the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.
Svensson and Coassolo are inventors on patents regarding BRP peptides for metabolic disorders. Svensson is a co-founder of Merrifield Therapeutics.
In before the “if people would eat fewer calories, they’d lose weight” crowd.
I don’t understand how Ozempic works. The literature says that it suppresses appetite, but severely overweight people never eat anything (according to the swverely overweight), and calorie restriction doesn’t work (according to “the experts”). How can Ozempic work? Magic? Sorcery? God’s will? Somehow, it causes people who don’t eat anyway to lose weight by suppressing their appetites?
So it is not available yet, and won’t be for several years at best unless the trial do not match the claims. Is that a fair analysis from a brief glance of the article?
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic . . .
“That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, . . .
Svensson and Coassolo are inventors on patents regarding BRP peptides . . .
= = =
Similar, but ‘in contrast’
Naturally occurring - where? What to eat to get it?
Naturally occurring - but patents?
Back in the seventies a girlfriend of mine used to get scrips for amphetamines. They worked. Of course she was a loose cannon from taking that sh*t and I had to leave her, but she kept the weight off.
Ask your doctor if Gila Monster venom peptides are right for you!
Sorry, but had a chuckle to find the name of this dietary molecule is BRP. Next one discovered will probably be called BLCH.
It must have something to do with the cost (about $1k for a one month supply, without insurance).
Made with real glycerin vibrafoam.
Okay, but it’s true. I took ozempic for awhile. But that was only after having lost 60 pounds on my own. And it was as simple as eating less. The ozempic helped me lose more, but the fundamental shift was changing the way I thought about food.
CC
I agree, I’m on it and amazingly I sometimes just don’t want to eat another bite.
It slows the rate at which food moves through your stomach, thus you feel full all the time & don’t eat or eat as much.
The downside: your stomach can be ‘paralyzed’ (gastroparesis) even after you get off the drug. Another adverse effect is ‘cyclic vomiting’ - can be disabling & also persist post drug. Muscle ‘wasting’ is an issue. If you get off the drug, the weight comes back.
I personally know 3 people that have had surgery due to adverse effects from either Ozempic or Wegovy.
LOL!!
After buying Ozempic, you CAN’T AFFORD FOOD!
Bariatrics, the study of weight loss, is complicated. It is not simply calories in and calories out. Weight gain is often the result of an insulin problem. Added to that is the type of food eaten and what the body craves. From what I understand, Ozempic corrects insulin resistance and suppresses both hunger and craving for carbohydrates and sugar.
bump for later....
If it tastes like chocolate or bacon, I'm all in.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.